This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fischli, W. Articles by Branca, Q. Search for Related Content PubMed PubMed Citation Articles by Fischli, W. Articles by Branca, Q.

Hypertension, Vol 18, 22-31, Copyright © 1991 by American Heart Association

ARTICLES

Ro 42-5892 is a potent orally active renin inhibitor in primates

W Fischli, JP Clozel, K el Amrani, W Wostl, W Neidhart, H Stadler and Q Branca
Pharma Research Department, F. Hoffmann-La Roche, Ltd, Basel, Switzerland.

The goal of the present study was to characterize the new renin inhibitor Ro 42-5892 in vitro and in vivo. In vitro, Ro 42-5892 inhibited purified human renin and human plasma renin specifically with an IC50 of 0.7 nM and 0.8 nM, respectively. In vivo, Ro 42-5892 reduced mean arterial blood pressure in sodium-depleted marmosets and squirrel monkeys with as low a dose as 0.1 mg/kg orally. Higher doses reduced pressure by 30-35 mm Hg in both species. The duration of blood pressure decrease with 3 mg/kg orally was more than 24 hours. Maximal changes of plasma renin activity, immunoreactive angiotensin I, and immunoreactive angiotensin II were observed at 15 minutes. Renin was reduced by 74 +/- 31%, angiotensin I by 85 +/- 14%, angiotensin II by 89 +/- 17%, and immunoreactive active renin was increased by 70 +/- 39%. However, unlike pressure, these maximal effects were only transient with complete recovery of renin at 60 minutes under still reduced levels of angiotensin I (61 +/- 24%) and angiotensin II (71 +/- 38%) and increased concentrations of active renin (86 +/- 30%). The blood pressure lowering was due to specific renin inhibition as exemplified by the influence of the kidney, sodium status, species, or stereoselectivity. Moreover, the reduction of arterial blood pressure was similar to the action of the angiotensin converting enzyme inhibitor cilazapril and was not associated with reflex tachycardia in contrast to the pure vasodilator minoxidil. We conclude that Ro 42-5892 is a potent orally active renin inhibitor acting mainly by inhibition of renin in an extraplasmatic compartment.

This article has been cited by other articles:

				J. Deinum, F. H.M. Derkx, and M. A.D.H. Schalekamp Improved Immunoradiometric Assay for Plasma Renin Clin. Chem., June 1, 1999; 45(6): 847 - 854. [Abstract] [Full Text] [PDF]

				G. Gorelik, L. A. Carbini, and A. G. Scicli Angiotensin 1-7 Induces Bradykinin-Mediated Relaxation in Porcine Coronary Artery J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 403 - 410. [Abstract] [Full Text]

				K. F. Hilgers, E. Bingener, C. Stumpf, D. N. Muller, R. E. Schmieder, and R. Veelken Angiotensinases Restrict Locally Generated Angiotensin II to the Blood Vessel Wall Hypertension, January 1, 1998; 31(1): 368 - 372. [Abstract] [Full Text] [PDF]

				C. A. M. van Kesteren, A. H. J. Danser, F. H. M. Derkx, D. H. W. Dekkers, J. M. J. Lamers, P. R. Saxena, and M. A. D. H. Schalekamp Mannose 6-Phosphate Receptor–Mediated Internalization and Activation of Prorenin by Cardiac Cells Hypertension, December 1, 1997; 30(6): 1389 - 1396. [Abstract] [Full Text]

				A. H. J. Danser, C. A. M. van Kesteren, W. A. Bax, M. Tavenier, F. H. M. Derkx, P. R. Saxena, and M. A. D. H. Schalekamp Prorenin, Renin, Angiotensinogen, and Angiotensin-Converting Enzyme in Normal and Failing Human Hearts : Evidence for Renin Binding Circulation, July 1, 1997; 96(1): 220 - 226. [Abstract] [Full Text]

				J. Bohlender, J. Menard, F. C. Luft, and D. Ganten Dose Effects of Human Renin in Rats Transgenic for Human Angiotensinogen Hypertension, April 1, 1997; 29(4): 1031 - 1038. [Abstract] [Full Text]

				J. Bohlender, A. Fukamizu, A. Lippoldt, T. Nomura, R. Dietz, J. Menard, K. Murakami, F. C. Luft, and D. Ganten High Human Renin Hypertension in Transgenic Rats Hypertension, January 1, 1997; 29(1): 428 - 434. [Abstract] [Full Text] [PDF]

				G. G. N. Serneri, M. Boddi, M. Coppo, T. Chechi, N. Zarone, M. Moira, L. Poggesi, M. Margheri, and I. Simonetti Evidence for the Existence of a Functional Cardiac Renin-Angiotensin System in Humans Circulation, October 15, 1996; 94(8): 1886 - 1893. [Abstract] [Full Text]

				J. Bohlender, J. Menard, J. Wagner, F. C. Luft, and D. Ganten Human Renin-Dependent Hypertension in Rats Transgenic for Human Angiotensinogen Hypertension, March 1, 1996; 27(3): 535 - 540. [Abstract] [Full Text]

				D. N. Muller, K. F. Hilgers, J. Bohlender, A. Lippoldt, J. Wagner, W. Fischli, D. Ganten, J. F. E. Mann, and F. C. Luft Effects of Human Renin in the Vasculature of Rats Transgenic for Human Angiotensinogen Hypertension, August 1, 1995; 26(2): 272 - 278. [Abstract] [Full Text]

				E. G. McMahon, P.-C. Yang, M. A. Babler, S. E. Bittner, O. D. Suleymanov, K. J. Cain-Janicki, L. J. Bedell, G. J. Hanson, and C. S. Cook Effects of SC-56525, a Potent, Orally Active Renin Inhibitor, in Salt-Depleted and Renal Hypertensive Dogs Hypertension, July 1, 1995; 26(1): 95 - 100. [Abstract] [Full Text]

				H. Kleinert, S. Rosenberg, W. Baker, H. Stein, V Klinghofer, J Barlow, K Spina, J Polakowski, P Kovar, J Cohen, et al. Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy Science, September 25, 1992; 257(5078): 1940 - 1943. [Abstract] [PDF]